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Binding Protein in Nonlesional Psoriatic Skin* 
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Cellular retinol (CRBP)- and retinoic acid (CRABP)-bind-
ing proteins were determin ed in samples of lesional and 
nonlesion al skin of psoriatic patients, before and during 
oral administration of a synthetic retinoid , Etretin (Ro 10-
1670). A 200% increase in CRABP levels, measured by the 
ability of the protein to bind retinoic acid, was observed 
in the normal skin during trea tment. The CRBP levels were 
Synthetic retinoids (vitamin A der ivatives) are now used widely for the treatment of several skin diseases, in-cluding psoriasis and skin mali gnan cies [1l. T heir mode of action at the molecul ar level is not known . It has been proposed that natural retin oids, retinol and retinoi c acid, 
exert their biolog ic fun ctions through specific intracellul ar bind-
ing proteins [2] . Two cellular retin o id-binding proteins ha ve been 
identified in many animal tissues, including skin. One protein 
binds specificall y retin o l and is ca lled cellular retinol-bindin g pro-
tein (CRBP); the o ther binds retinoic acid and is call ed cellular 
retinoic acid-binding pro tein (CRABP) r2]. In spite of the fact 
that CRABP also binds sy nthetic retinoids possessing a ca rboxyli c 
g roup [3], it is not known w hether th ey exert th eir pharmacologic 
action throu gh the pathway suggested for natural retin o ids [2]. 
To address this question we have exa mined w hether adm inistra-
tion of a synthetic retinoid (Etretin, Ro 10-1670) to psori ati c 
patients influences th e level ofCRBP and /o r C RABP. We report 
here that th e level of C RABP, but not C RBP, is augmented 
during therapy in nonlesional psori atic sk in . 
MATERIALS AND MET HODS 
Patients and Skin Sampling Nineteen adu lt psoriatic patients 
(15 males , 4 females, 21-77 yea rs of age, mean age 59 years) 
non treated fo r at least 1 month before entering th e study ga ve 
their info rm ed consent fo r skin sa mplin g. The protoco l has been 
accepted by the loca l ethical committee. The patients were trea ted 
ora ll y with Etretin (Ro 10-1 670) in doses of 0.75 m g/kg/day for 
4 weeks. Skin sa mples were obtained before and durin g treatment 
from nonlesional skin, distant from a psoriati c plaque, at th e 
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Abbreviations: 
CRABP: cellular rctinoic acid-binding protein 
CHBP: cellular retinol-binding protcin 
Etretin (Ro 10-1670): trimethylmcthoxyphenyl retinoic acid 
SRBP: serum retinol-binding protein 
not altered during therapy. The results show that CRBP 
and CRABP are independently regulated in human skin 
and suggest that synthetic retinoids may exert their phar_ 
macologic effects by interfering with the regulation of nat-
ural retinoic acid receptors . J Invest D ermatol 87:122-124, 
1986 
anterio r aspect of th e thi gh; a keratome set at 0.180 mm was used 
and histologic assess ment of the sa mples was don e. Stable diseased 
ski n (referred to as psoriatic plaque) was taken w ith a kera tome 
set at 0.280 mm before and durin g trea tment and also assessed 
histologicall y. The skin sa mples were lyophilized. 
Preparation of Supernatants About 15 mg o flyophili zed skin 
tiss ue sa mples were full-specd homogeni zed durin g 30 s, 3 times 
in 800 J-Ll extra ction buffer (Tris/HCl 50 mM , NaCl 25 mM, 
EDT A 2.5 mM, pH 7.5) using a tiss ue homogeni zed Polytron_ 
PT7 (Kinemati ca, Lucern e, Switzerl and). Supernatants were ob_ 
tain cd by centrifu ga tion at "100,000 J? for 60 min at 4°C and im_ 
mediately used fo r assays. Protein content was determined usin g 
bovine serum albumin as standard [4] . D NA was es timated using 
ca lf thymus DN A as standard [5] . 
Charcoal-Dextran and Gel Filtration Assay Binding pro_ 
teins were quantitated after incubation o f th e supernatant with 50 
nM all fYIIIlS-[l1 , 12-3H]rctinoi c acid (30 Ci/ mmol , g ift ofF. Hoff_ 
mann-La Roche, Basel, Switzerland) o r all trll lls-[15-3H]retinol 50 
nM (14.3 C i/ ml1lol , New Eng land Nuclear, Drcieich, W es t Ger_ 
many) in the presence or absence of an excess of unlabeled reti-
noids as described previously (6). Purity of th e retinoids was 
checked by high-performance liquid chromatography [7) . To pre-
pare alcoho li c sqlutions o f the retinoids, the antioxidant 
a-tocopherol was repl aced by butylated hydroxy tolu ene (500 
J-Lg/ml) . A charcoa l-dextran tcchniqu e was developed for skin to 
measure th e binding proteins [8,9] in duplica te. Briefl y, after 
incubation of the supern atant with labeled retinoids for 16 h at 
4°C, 400 J-Ll of charcoa l-dextran suspension (0.8% charcoal, 0.08% 
dextran T70, 0.25 M sucrose, 1 mM EDTA in 0 .01 M Tris / H Cl, 
pH 7.5) were added and mixed with 90 J-Ll of the supernatant 
incubate. After 15 min , the tubes w ere centrifuged and radioac_ 
tivity of supernatants assessed in a liquid scintillation counter 
(Beckma n, LS-1800) using 8 ml BioAuor (New England Nuc!ear). 
Binding activity was expressed as pmol of the liga nd specifically 
bound per mg of protein or per mg of DNA . T he specific binding 
was calculated from the radioactivity recovered with or without 
a 200-fold excess of unlabeled retinoids. Supernatant (320 J-Lg 
protein in 100 J-Ll) incubated with [3H]retinoic acid as described 
above was submitted to gel filtration on a Sephadex G75 colu mn 
(0.8 x 15 cm) equilibrated with extraction buffer (6). Fraction 
of 300 J-LI were collected and radioactivity assessed as for the 
charcoal-dextran assay. 
0022-202X/86/S03.S0 Copyright © 1986 by The Society for Inves tiga tive Dermatology, Inc. 
122 
VOL. 87, NO, 1 JULY 1986 CRABI' MODULATION IN HUMAN SK IN 123 
Table I. Levels of CRABP and CRBP in Nonlesiona l and Lesiona l Skin Samples Before and During Etretin Therap y 
(Mean ± SE) 
CRABP CRI3P 
Skin pmol.mg - I Protein pmo].mg - I DNA pmol,m g - I Pro tei n pm o].mg - I DNA 
N on lesional" 
Before ET" (N 9) 2,40 ± 0,27 41.83 ± 4,7 1.34 ± 0,26 23,36 ± 4,53 
D uring ET (N = 10) 6,25 ± 1.75' 11 4,50 ± 32' 1.40 ± 0.46 25.65 ± 8.43 
Les iona ]" 
Before ET (N = 16) 
D urin g ET (N = 9) 
7.43 ± 1.77 165.49 ± 39.4 1.1 9±0.33 26.50 ± 7.35 
6.91 ± 2. 13 145.09 ± 44.72 1. 5? + 0.56 3 1 .9? + 11. 76 
All sa mples were as,"yed in dupli cate. 
aSkin sa mples takeJl in skin of normal appearallce. 
bET , Etretin (0.75 mg/ kg/day) therap y. 
'p < 0.00 1. 
'S table psoriatic plaques. 
RESULTS 
Table [ shows that there was a signifi cant (p < 0.001) increase of 
CRABP per m g of protein in the non les io nal ski n during Etretin 
therapy w hereas C RBP was o nl y moderately and nonsignifican tl y 
elevated. This effect was observed although the total protein con-
tent in the sk in was also signifi cantl y in creased during Etretin 
therapy. When CRABP and CRBP w ere related to the DNA 
content similar results were obta ined. 
[n psoriati c plaq ues, as previously reported [8], pretherapy val-
ues were significantly hig her for CRABP bu t not CRBP as com-
pared with nonles ional skin . During Etretin therapy, no signif-
icant chan ges were observed either for CRABP or CRBP, although 
the total protein content was increased (Table I). N o serum ret-
inol-bindin g protein (SRBP) (which can bind both retinol and 
retinoic acid il"l lIilro) with any effcctive retinoid binding affinity 
was detected in the skin extracts by either transthyretin-Sep harose 
affinit y chromatography o r immunoblotting using a goat anti-
human SRBP seru m [9,10]. 
Table 1I shows the indi vidual va lues for CRABP observed in 
th e 7 patients who could be studi ed both before and during Etretin 
Table II. CRABP Values in 7 Psoriatic Patients Analyzed 
Before and During Etretin Therapy 
CRABP 
Skin and Week of In crease 
Patient No . Treatment" pl11o]'m - I Protein in (Yoh 
Nonlesional 
131" 2.27 
0.5 7. 13 +214 
2 8.76 +286 
3 7.87 +247 
2 BT 2.25 
3 4.16 +85 
Lesional 
3 BT 3.49 
I 4.99 +43 
4 BT 5.47 
3 6.24 + 14 
5 BT 5.82 
4 7.68 +32 
6 BT 6.32 
3 6.45 +2 
7 BT 8.67 
2 8.84 +2 
'Etrctin 0.75 m g/J.tg/day. 
'CalculateQ from va lue obta ined before treatment. 
(Before treatment. 
therapy. A considerable increase (2]4%) was no ted in no nlesional 
sk in as soo n as 3 days afte r administration of the drug. In psoriatic 
plaques , on ly a m oderate increase of C RABP was seen in som e 
patients, who had the lowest pretherapy va lues. 
Fig 1 shows the elution profile observed by gel filtration anal-
ys is on Sephadex G75 ofa supern atant of non Ie siona I ski n sa mples 
obtai ned during Etretin therapy incubated with [3H]retinoic acid; 
thiS eluti o n profile is iden tical with that of normal hum an nonle-
sional and Icsiona l psoriatic skin as previously described '[6,8,9]. 
In all the sk lt1 samples C RABP and C HBP were found to be about 
15,000 in molecu lar wei ght. The appa rent K" for C H.ABP of 
nonlesiona l skin obtained durin g Etretin therapy were m eas ured 
w ith charcoa l-dextran technigue as described previo usl y [8]. A 
value of] 37 nM was fo und w hich co rresponds well with values 
reported for epidermis [6] and skin 1.8,9]. 
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Figure 1. Gel filtration analysis 011 Sephadcx G75 column of hum an 
nonksional skin obtained during Et;etin ther:IPY·. Supern atant (320 ILg 
protell1) was II1cubated wlth 50 nM r Hlrctll10lc aCid (opell circlcs), in the 
presence of an excess of200-fold retinoic acid (solid circlcs) or retino l (so lid 
Iriallg/cs) . 
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DISCUSSION 
Systemic administration o f an acidic retinoid significantly in-
creases CRABP, which binds acidic retinoids, but not CRBP, 
w hi ch binds retinol. It is unlikely that this reflects a nonspecific 
event as only CRABP was increased and CRABP values were 
calculated on both a DN A and a protein basis. Moreover, meth-
odologic requirements such as saturability , competition , and 
specificity were satisfi ed [6,9]. Moreover, in vivo an overload 
with the acidic ligand would result in an underestimation ofCRABP 
rather than in an increase of the specific binding si tes. Therefore, 
the problem of un occupied vs occupied receptors [11] is not rel-
evant to the present results. Thus the development of an assay 
that would distin guish free from bound form s of CRABP was 
not necessary. 
Another important observation related to the action of the syn-
thetic retinoid was the fact that C RABP was not modified in the 
lesional skin in which it is likely that the highest levels have already 
been reached and cannot be further increased (see Table II). That 
the increase of CRABP during Etretin therapy is not due to an 
intrinsic abnormality of the nonles ional psoriatic skin is supported 
by the preliminary observation of a similar increase in nondiseased 
skin of patients treated with Etretin for other diseases such as 
hyperkeratOtic eczema and li chen planus (data not shown). 
T he binding affinity of CRABP for retinoic acid in Etretin-
treated patients was un changed as compared with nontreated pa-
tients, indicating that the increase in binding capacity refl ects an 
actual increase in the number of binding sites, i.e., CRABP mol-
ecules. 
It has been suggested that C RABP and CRBP may play a direct 
role in the biologic expression of retinoid activity in a manner 
analogous to steroid ho rmone receptor [2]. Steroid hormon es 
most often down-regulate their own receptors rather than in-
creasing the number of binding sites (reviewed in [12]) . Animal 
studies indicate that retinoid-defi cient diets redu ce the levels of 
CRBP in several tissues and those of CRABP only in the skin 
[13]. O ur findin gs in human skin are therefore concordant with 
these observations and suggest that, at least for skin C RABP, the 
number of binding sites is influenced by the amount of ligand 
available. Whether this elevation is an important event in the 
responsiveness of a given tissue to synthetic retinoids with a car-
boxyl group in the CI S position rem ains to be analyzed. A study 
of CRABP binding sites in organs less responsive than the skin 
to synthetic retinoid therapy should give some insight into this 
question. 
Synthetic retinoids do not bind to SRBP and are not, therefore, 
delivered to the target cells in a way similar to that of retinol [14] . 
It has, therefore, been sugges ted that synthetic retinoids might 
not exert thei r pharmacologic action through the pathway of 
natural vitamin A derivatives. However, it has b.een shown that 
the synthetic retinoids used in human therapy bind to rat C RABP 
in vitro and have an acidic group in the CIS position [15,16] . 
Moreover, an increase of CRABP, but not CRBP was observed 
in psoriatic plaques as compared with nonlesional skin ; this cor-
relates with the observation that psoriatic plaques res pond more 
readily to synthetic acidic retinoids than the nondiseased skin [8]. 
The elevation of CRABP durin g synthetic retinoid therapy is' 
a furth er but yet indirect indication that these compounds interact 
with the natural retinoic acid-binding protein in humans. 
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